Mumbai-based Steris Healthcare plans to launch IPO in FY 2026-27

Steris Healthcare, a Mumbai-headquartered pharmaceutical leader with operations in Navi Mumbai, has announced a Rs 50 crore multi-pronged growth strategy, including a major expansion into South India, a doubling of production capacity, and plans to launch its initial public offering (IPO) in FY 2026-27. 

The company, which recently crossed Rs 100 crore in annual sales, said it aims to solidify its national presence and enhance its ability to deliver innovative, affordable healthcare solutions.

Establishing manufacturing facility

As part of its strategic expansion, Steris Healthcare will establish a state-of-the-art manufacturing facility in South India, targeting key markets in Kerala, Tamil Nadu, Hyderabad (Telangana), and Bengaluru (Karnataka).

The company said the move is designed to streamline supply chains and strengthen its reach in high-demand regions. The new plant will double Steris' production capacity by 100%, adding (XX) units to its existing infrastructure, enabling the company to meet growing domestic and international demand while adhering to stringent quality standards, it said.

Focused on launching new products

In addition to scaling operations, Steris Healthcare will launch new medications and healthcare products aimed at addressing critical therapeutic needs. 

Notably, the expansion is also expected to generate 800 new jobs across manufacturing, R&D, sales, and logistics, fostering economic growth in South India.

"This Rs 50 crore expansion and our upcoming IPO in FY 2026-27 mark a defining chapter in Steris' journey. By deepening our roots in South India and investing in cutting-edge therapies, we are poised to serve millions more patients while creating long-term value for our stakeholders. Our focus remains on making healthcare accessible without compromising on innovation," said Jeevan Kasara, Director & CEO of Steris Healthcare.

Renuka Kasara, Director of Steris Healthcare, added: "Crossing Rs 100 crore in sales this year is a testament to our team's dedication and the trust healthcare providers have placed in us. As we embark on this expansion phase, we remain committed to maintaining the highest standards of quality while expanding our product portfolio to serve diverse medical needs across India."

The proposed IPO, slated for FY 2026-27, will support Steris' growth objectives, including infrastructure development, R&D advancements, and market diversification.

The company said it is collaborating with financial advisors for compliance with regulatory frameworks and to align with investor expectations for a successful public listing.